Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552373 | 0.80 | PGR (0.45) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL4480236 | 0.80 | PDE3B (0.41) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL8082246 | 0.80 | PGR (0.46) | IL4I1MMP12PDE3BPDE3APGR | |
| SCHEMBL3600619 | 0.78 | IL4I1 (0.44) | IL4I1MMP12PDE3BPDE3APGR | |
| SCHEMBL27519112 | 0.76 | PDE3B (0.41) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL7281256 | 0.76 | GAA (0.44) | IL4I1MMP12PDE3BPDE3AADRB2 | |
| SCHEMBL13545333 | 0.76 | MMP12 (0.39) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL8083106 | 0.76 | ADRB2 (0.38) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL31731496 | 0.75 | PGR (0.37) | IL4I1MMP12PDE3BPDE3AAHR | |
| SCHEMBL252672 | 0.75 | PGR (0.37) | IL4I1MMP12PDE3BPDE3AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-2162433-A2 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | IL4I1 3781/4885MMP12 4885/4885PDE3B 375/4885 |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | IL4I1 2799/4885MMP12 4883/4885PDE3B 396/4885 |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | IL4I1 1080/4885MMP12 3216/4885PDE3B 286/4885 |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | IL4I1 1915/4885MMP12 4876/4885PDE3B 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.